Upcoming gene therapies for diabetic neuropathy, osteoarthritis and wet age-related macular degeneration are on track for launch in the US within the next three years and have expected patient populations in the multi-millions, which could present a significant challenge for payers, including Medicare and state Medicaid programs.
To date, the individual impact of gene therapies on the market, even with prices that approach and exceed $1m, may seem relatively manageable. Most gene therapies on the market and due to reach it in the next two years target patient populations that are well below the 200,000 statutory threshold for orphan drugs, according to a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
